Kronos Bio LLC (KRON) Osake Kurssi
Kronos Bio LLC Kurssi
Liikevaihto on kasvanut 78,7 % vuodessa viimeisten 2 vuoden aikana 9,85 M USD:een. Kronos Bio LLCn nettomarginaali on nyt −874,1 %, noussut −4 192,4 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 2,30 USD, eli yli nykyhintaa 160,8 %. 7 analyytikosta 6 suosittaa ostoa — kokonaiskonsensus on Osta.
Kronos Bio LLC osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Kronos Bio LLC liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Kronos Bio LLC -osakkeesta
The business model of Kronos Bio Inc. focuses on developing and commercializing novel therapies for the treatment of cancer and other serious diseases. By leveraging its proprietary platform, the company aims to identify and target specific vulnerabilities in cancer cells, resulting in more effective and personalized therapies. Kronos Bio Inc. employs a multi-disciplinary approach, combining expertise in chemistry, structural biology, and genomics to accelerate the discovery and development of potential drug candidates. With a strong commitment to improving patient outcomes, Kronos Bio Inc. is devoted to advancing its pipeline of innovative medicines to address unmet medical needs in oncology and beyond.
Kronos Bio Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Kronos Bio Inc in the market are other biotechnology companies operating in the same therapeutic areas. Some prominent competitors include XYZ Biotech, ABC Biopharma, and LMN Therapeutics. However, Kronos Bio distinguishes itself through its innovative drug discovery platform and its focus on personalized medicine. With its cutting-edge technology and strong pipeline, Kronos Bio Inc stands out amidst competition and aims to revolutionize the field of biotechnology.
Kronos Bio Inc is a biopharmaceutical company that focuses on developing novel therapies for cancer and other serious diseases. Established in 2017, the company is based in San Mateo, California. Kronos Bio Inc utilizes its proprietary discovery platform to identify and target dysregulated transcription factors, which play a crucial role in disease progression. By developing small molecule modulators, they aim to disrupt disease-driving transcriptional programs. With a focus on precision medicine, Kronos Bio Inc aims to provide effective and personalized treatment options for patients. They have partnered with leading academic institutions and have a diverse pipeline of potential therapeutics.
Kronos Bio Inc, a leading biopharmaceutical company, has achieved remarkable milestones to date. The company has successfully developed and advanced several innovative therapeutic programs. Notably, Kronos Bio Inc received the prestigious Breakthrough Therapy Designation by the U.S. FDA for its novel drug candidate, entospletinib. This designation recognizes the remarkable potential of entospletinib in treating patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Kronos Bio Inc has also formed strategic partnerships with renowned organizations to expedite the development and commercialization of its pipeline. These milestones reflect the commitment and groundbreaking research efforts of Kronos Bio Inc, positioning the company as a frontrunner in the biopharmaceutical industry.
Kronos Bio Inc is primarily present in the United States.
Kronos Bio Inc represents a strong set of values and a clear corporate philosophy. The company prioritizes innovation and scientific excellence in its efforts to develop transformative therapies for cancer patients. Kronos Bio Inc firmly believes in collaboration and maintains partnerships with leading academic institutions and industry leaders to accelerate their research and development. With a focus on precision medicine, the company aims to uncover and target molecular vulnerabilities to address unmet medical needs. By leveraging its expertise in targeted protein degradation, Kronos Bio Inc strives to make a significant impact in the field of oncology.
Analyytikot asettavat tällä hetkellä Kronos Bio LLC-osakkeelle keskimääräisen tavoitehinnan 2,30 USD (mediaani: 2,30 USD), mikä merkitsee +160,8 % viimeisimpään hintaan verrattuna. Konsensus perustuu 7 analyytikkoarvioon.
7 analyytikkoa arvioi tällä hetkellä Kronos Bio LLC-osaketta: 6 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Kronos Bio LLC-yhtiöltä 12,83 M USD liikevaihtoa ja −1,36 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Kronos Bio LLC-osake noteerataan hintaan 0,79 EUR (0,88 USD).
Kronos Bio LLC-osake (KRON) on listattuna 1 pörssissä, muun muassa: NASDAQ (KRON).
The company Kronos Bio Inc. is a biotechnology company that focuses on the development and production of novel therapeutics for cancer patients. The company is headquartered in Cambridge, USA and is one of the most promising start-ups in the pharmaceutical industry. Kronos Bio's business model is based on a wide range of research topics, including biomarker discovery, drug research, and preclinical and clinical study developments. Kronos Bio aims to explore new treatment options for cancer patients based on genetic and epigenetic mutations to advance personalized medicine. Kronos Bio's products focus on cancer treatments and consist of a pipeline of therapeutics in various stages of development. For example, the drug "KB-0742" is in preclinical development. This drug could interact with a specific mutation in a cancer-related gene to selectively destroy cancer cells. Another product of the company is "KB-0742", a potentially promising drug against myelodysplastic syndromes (MDS) and leukemia. It is currently in clinical development and initial results show potential efficacy against MDS. Kronos Bio aims to distribute its products in different markets worldwide and secure the intellectual property of its products through patents and licenses. To test and validate the efficacy of their products, Kronos Bio works closely with government organizations, universities, and private laboratories. Kronos Bio's research focus is based on the discovery of novel therapeutics through the combination of genetic and chemical approaches. Their research team consists of industry veterans, scientists, and data scientists who develop unique and tailored models to test and validate the effects of their products. In summary, Kronos Bio Inc. has a smart and ambitious business model. The company places special emphasis on the development of personalized medicine and explores innovative products and technologies to provide cancer patients with the best possible treatment approach. With its diverse pipeline and project development, Kronos Bio strives to bring unique therapeutics to the market to improve the lives of cancer patients worldwide.
odotettu liikevaihto Kronos Bio LLC on 12,83 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Kronos Bio LLC on −82,31 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Kronos Bio LLC:n hinta-voitto-suhde (P/E) on tällä hetkellä −0,65. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Kronos Bio LLC-osakkeen arvostusta.
Kronos Bio LLC:n hinta-myynti-suhde (P/S) on tällä hetkellä 4,14. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Kronos Bio LLC-osakkeen arvostuskennuslukuna.
Kronos Bio LLC:n Eulpool-laatuscore on 2/10.
Kronos Bio LLC:n ISIN on US50107A1043. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Kronos Bio LLC:n WKN on A2QD64. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Kronos Bio LLC:n ticker on KRON. Tämä pörssinoteeraus käytetään Kronos Bio LLC-osakkeiden kauppaan pörssissä.
Kronos Bio LLC osake
Kronos Bio LLC vertaisryhmä
Kronos Bio LLC Ticker
Kronos Bio LLC FIGI
Kaikki tunnusluvut ja syvällinen analyysi Kronos Bio LLC:sta
Meidän osakeanalyysimme Kronos Bio LLC-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Kronos Bio LLC:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: